LENZ Therapeutics (LENZ) Amortizatization of Intangibles (2022 - 2026)
LENZ Therapeutics (LENZ) reported Amortizatization of Intangibles of $316000.0 for Q1 2026, down 72.13% year-over-year from $1.1 million in Q1 2025, and down 48.03% on a QoQ basis from $608000.0 in Q4 2025.
LENZ Therapeutics (LENZ) has 5 years of Amortizatization of Intangibles data on file, last reported at $316000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 72.13% year-over-year to $316000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 46.86% YoY) and the FY2025 annual result came in at $3.4 million, down 15.14% from the prior year.
- Amortizatization of Intangibles declined to $316000.0 in Q1 2026 per LENZ's latest filing, from $608000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.4 million in Q4 2024 and bottomed at -$45000.0 in Q1 2022.
- The 5-year median for Amortizatization of Intangibles is $585000.0 (2022), against an average of $649937.5.
- The widest annual swing landed in 2024, when Amortizatization of Intangibles soared 4947.37%; it then plunged 72.13% in 2026.
- Tracing LENZ's Amortizatization of Intangibles over 5 years: stood at $1.1 million in 2022, then sank by 54.42% to $511000.0 in 2023, then surged by 178.67% to $1.4 million in 2024, then sank by 57.3% to $608000.0 in 2025, then tumbled by 48.03% to $316000.0 in 2026.
- Per Business Quant, the three latest LENZ Amortizatization of Intangibles figures stand at $316000.0 (Q1 2026), $608000.0 (Q4 2025), and $779000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | 316,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 316,000.00 |
| Mar 31, 2026 | 316,000.00 |
| Dec 31, 2025 | 608,000.00 |
| Dec 31, 2025 | 608,000.00 |
| Sep 30, 2025 | 779,000.00 |
| Sep 30, 2025 | 779,000.00 |
| Jun 30, 2025 | 888,000.00 |
| Jun 30, 2025 | 888,000.00 |
| Mar 31, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.13 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Dec 31, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 959,000.00 |
| Jun 30, 2024 | 959,000.00 |
| Mar 31, 2024 | 275,000.00 |
| Mar 31, 2024 | 275,000.00 |
| Dec 31, 2023 | 511,000.00 |
| Dec 31, 2023 | 511,000.00 |
| Sep 30, 2023 | 527,000.00 |
| Sep 30, 2023 | 527,000.00 |
| Jun 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 19,000.00 |
| Dec 31, 2022 | 1.12 Mn |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 562,000.00 |
| Sep 30, 2022 | 562,000.00 |
| Jun 30, 2022 | -38,000.00 |
| Jun 30, 2022 | -38,000.00 |
| Mar 31, 2022 | -45,000.00 |
| Mar 31, 2022 | -45,000.00 |